Special Issue "Canine Cancer Immunotherapeutics"
A special issue of Veterinary Sciences (ISSN 2306-7381).
Deadline for manuscript submissions: closed (30 September 2018) | Viewed by 24043
Interests: molecular pathogenesis of feline immunodeficiency virus infection; vaccine development in animal models for HIV-1 AIDS; use of cytokines and TLR ligands as vaccine adjuvants; tumor immunology in companion animal cancer
Special Issues, Collections and Topics in MDPI journals
Recent studies have revealed the power of immunotherapeutics for human cancer. In particular, agents that activate the immune system by blocking specific anti-inflammatory check points, as well as engineered T cells have proven to be effective in certain human patient populations. However, important issues relating to these therapies must be addressed and include significant toxicities and selection of patients who will most likely respond to these therapeutics. Furthermore, delivery technologies for these drugs warrant further optimization to limit off-target toxicities. Canine cancer patients are likely to benefit from these promising immunotherapeutic modalities, and may also provide a powerful model for testing of new generations of immunotherapeutics. Recent reports within veterinary research describe canine-specific antibodies with potential as checkpoint inhibitors, as well therapeutic canine cancer vaccines with some efficacy. Together these therapeutic modalities may significantly impact therapeutic protocols for certain canine cancers in the future and therefore present a potent area of focus for clinical canine cancer research.
Original manuscripts that address development and testing of cancer immunotherapeutics for canine cancers are solicited for this Special Issue. Studies that use innovative or novel technologies to identify specific cancers or canine patient populations more likely to respond to immunotherapeutics, are also encouraged for submission.
Dr. Ellen E. Sparger
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Veterinary Sciences is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- canine cancer
- cancer immunotherapeutics
- animal models
- checkpoint inhibitors
- engineered T cells
- cancer vaccines
- immune system targets
- immune modulation in cancer
- immunotherapy toxicities
- One Health
- One Medicine